Umang Swami has been awarded the SWOG Dr. Vogelzang Scholar Award

The Nicholas Vogelzang SWOG GU Scholarship supports early-stage investigators in genitourinary cancers, allowing them to attend two SWOG group meetings annually. Each scholar is paired with a senior mentor for guidance throughout their early career.

Umang Swami

Umang Swami is an Assistant Professor in the Division of Oncology at the Huntsman Cancer Institute, University of Utah, specializing in medical oncology with a focus on genitourinary cancers.

He earned his medical degree from Sawai Man Singh Medical College in India and gained research experience as a Visiting Scientist at the Montefiore-Einstein Cancer Center in New York, where he worked on phase I studies for advanced solid tumors.

Dr. Swami completed his residency in Internal Medicine at St. Barnabas Hospital and a Hematology-Oncology fellowship at the University of Iowa, where he also obtained a Master’s in Clinical Investigations. He has published over 110 peer-reviewed articles and presented his research at major conferences such as ASCO and AACR, highlighting his commitment to advancing oncology.

Dr. Swami is also dedicated to mentoring the next generation of oncologists and consistently receives high patient ratings for his compassionate, personalized care. His blend of clinical expertise, research leadership, and commitment to education makes him a vital asset to the Huntsman Cancer Institute and the oncology community.

Umang Swami:

“Honored to receive this recognition from SWOG, established in memory of esteemed leader and mentor Dr. Nicholas J. Vogelzang. This opportunity empowers young investigators through mentorship from SWOG’s exceptional leaders. Learn more.”

Neeraj Agarwal:

“Packed room SWOG GU committee 2024 fall meeting, with opening remarks by Seth Lerner.

Congrats Umang Swami for receiving SWOG Dr. Vogelzang scholar award, consider supporting The Hope Foundation for Dr. Vogelzang fund.”

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.

Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.